Company Filing History:
Years Active: 2019
Title: The Innovative Contributions of Chi-Hui Liang
Introduction
Chi-Hui Liang is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of biotechnology, particularly in the development of innovative methods for virus detection and cancer treatment. With a total of 2 patents, his work has garnered attention for its potential applications in medical science.
Latest Patents
Chi-Hui Liang's latest patents include groundbreaking technologies. One patent focuses on glycan arrays for high throughput screening of viruses. These glycan arrays are designed to detect and distinguish between various sub-types and strains of influenza virus. The methods disclosed involve using nanoparticle amplification techniques in assays. Additionally, the patent describes sandwich assays that utilize gold nanoparticles conjugated to phage particles, which are specific to influenza virus antibodies. This allows for the detection of multiple serotypes in a single reaction. The array comprises a plurality of glycans directed to specific target hemagglutinin (HA) of the influenza virus. Furthermore, the patent includes detector molecules made of noble metals conjugated to phage display particles expressing antibodies against hemagglutinin and neuraminidase binding agents.
Another significant patent by Chi-Hui Liang addresses antibody-mediated anti-tumor activity induced by Reishi mushroom polysaccharides. This patent provides immunogenic compositions, cancer vaccines, and methods for treating cancer that include FMS, the fucose-enriched polysaccharide fraction from Reishi F3. The compositions consist of fucose-enriched Reishi polysaccharide fraction (FMS) with a molecular weight of approximately 35 kDa. The FMS is isolated through size-exclusion chromatography from Reishi F3 and comprises polysaccharides with a backbone selected from 1,4-mannan and 1,6-α-galactan, linked to a terminal fucose-containing side-chain. The immunogenic compositions also include glycolipid adjuvants, and the antibodies generated bind to cancer cells with specific antigens.
Career Highlights
Chi-Hui Liang is affiliated with Academia Sinica, a prestigious research institution in Taiwan. His work has significantly advanced the understanding of viral infections and cancer therapies. His innovative approaches have the potential to improve diagnostic methods and treatment options in the medical field.
Collaborations
Chi-Hui Liang has collaborated with notable colleagues, including Chi-Huey Wong and Chung-Y